The OBRI was pleased to present our latest research at both the Annual European Congress of Rheumatology Congress of Rheumotology (EULAR) in Amsterdam, NL, June 13-16, 2018 and the American College of Rheumatolgy (ACR) Annual Scientific Meeting in Chicago, IL, October 19-24, 2019.
In Amsterdam, the poster Anti-CCP and Rheumatoid Factor as Predictors of Sustained Clinical Remission in Rheumatoid Arthritis Patients: Data from a Canadian Observational Cohort was included in a guided poster tour.
Other OBRI scientific posters presented at EULAR 2018 include:
- Impact of Residential Area on the Profile of Rheumatoid Arthritis Patients Initiating their First Biologic DMARD: Results from the Ontario Best Practices Research Initiative (OBRI);
- Time to Discontinuation of Biologic Therapy by Mechanism of Action in Rheumatoid Arthritis: Results from the Ontario Best Practice Research Initiative (OBRI) Cohort;
- Collection of Anti-Rheumatic Medication Data from Both Patients and Rheumatologists Shows Strong Agreement in a Real World Clinical Cohort: The Ontario Best Practices Research Initiative (OBRI) a Rheumatoid Arthritis Cohort.
- Collection of Anti-Rheumatic Medication Data from Both Patients and Rheumatologists Shows Strong Agreement in a Real World Clinical Cohort: The Ontario Best Practices Research Initiative (OBRI) a Rheumatoid Arthritis Cohort.
At the ACR meeting in Chicago, the following OBRI scientific posters were presented:
- Development of an Algorithm for the Classification of Cardiovascular Comorbidities in a large Rheumatoid Arthritis Registry: Data from the Ontario Best Practices Research Initiative.
- Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative.
- Time to Discontinuation of Biologic Therapy by Mechanism of Action in Rheumatoid Arthritis: Results from The Ontario Best Practice Research Initiative (OBRI) Cohort.
- A Descriptive Analysis of Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs For Treatment of Rheumatoid Arthritis: Data From the OBRI Database.